Cancer Research Cancer Epigenetics  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 47, 5875-5879, November 15, 1987]
© 1987 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Park, J.-G.
Right arrow Articles by Gazdar, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, J.-G.
Right arrow Articles by Gazdar, A. F.

Chemosensitivity Testing of Human Colorectal Carcinoma Cell Lines Using a Tetrazolium-based Colorimetric Assay1

Jae-Gahb Park2, Barnett S. Kramer, Seth M. Steinberg, James Carmichael3, Jerry M. Collins, John D. Minna and Adi F. Gazdar

National Cancer Institute-Navy Medical Oncology Branch, Naval Hospital, Bethesda, Maryland 20814-5105 [J-G. P., B. S. K., J. C., J. D. M., A. F. G.], and Biostatistics and Data Management Section, Clinical Oncology Program [S. M. S.] and Clinical Pharmacology Branch [J. M. C.], National Cancer Institute, Bethesda, Maryland 20892

The in vitro chemosensitivity of 11 human colorectal cell lines to seven chemotherapeutic agents was determined using a semiautomated tetrazolium-based colorimetric assay (MTT assay). Four of the cell lines were from primary tumors and seven from metastases. Eight lines were from patients with no prior chemotherapy. From assay results, we predict 5-fluorouracil (5-FU) to be the sole active agent of the seven tested. This is based on two observations: the range of drug concentrations which produced 50% inhibition of cell growth was greatest with 5-FU (388-fold versus 5- to 30-fold with the other six agents); and the area under the curve (AUC) which produced 50% growth inhibition was within a clinically achievable range only for 5-FU. Since the assay AUC of 5-FU at 50% inhibition was in a clinically achievable range for only two of the 11 cell lines, we performed a multivariate analysis to explore parameters which predict 5-FU sensitivity. In the best fitting model, sensitivity was positively correlated with cloning efficiency in media and with cell surface TAG-72 (a tumor-associated glycoprotein found on epithelial tumors of ovary, lung, colon, and breast origin) expression. If validated with an in vivo test such as the nude mouse model, the MTT assay could be very useful in new drug screening for colorectal carcinoma, for examining combination chemotherapy for synergy, for exploring strategies for biochemical modulation, and perhaps in individualizing therapy when cell lines can be established from a patient.

1 The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Navy or the Department of Defense.

2 To whom requests for reprints should be addressed, at Department of Surgery, College of Medicine, Seoul National University and Seoul National University Hospital, Seoul, 110, Korea.

3 Present address: Department of Clinical Oncology, Newcastle General Hospital, Newcastle, England.

Received 2/ 2/87. Revised 5/20/87. Accepted 8/ 3/87.




This article has been cited by other articles:


Home page
J. Thorac. Cardiovasc. Surg.Home page
T. Yoshimasu, S. Oura, I. Hirai, T. Tamaki, Y. Kokawa, K. Hata, F. Ohta, R. Nakamura, M. Kawago, H. Tanino, et al.
Data acquisition for the histoculture drug response assay in lung cancer
J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 303 - 308.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Bian, T. D. Giordano, H.-J. Lin, G. Solomon, V. P. Castle, and A. W. Opipari Jr.
Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas Stimulation
J. Biol. Chem., February 6, 2004; 279(6): 4663 - 4669.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. J. Welsh, R. R. Williams, A. Birmingham, D. J. Newman, D. L. Kirkpatrick, and G. Powis
The Thioredoxin Redox Inhibitors 1-Methylpropyl 2-Imidazolyl Disulfide and Pleurotin Inhibit Hypoxia-induced Factor 1{alpha} and Vascular Endothelial Growth Factor Formation
Mol. Cancer Ther., March 1, 2003; 2(3): 235 - 243.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Jacob, M. Aguado, D. Fallik, and F. Praz
The Role of the DNA Mismatch Repair System in the Cytotoxicity of the Topoisomerase Inhibitors Camptothecin and Etoposide to Human Colorectal Cancer Cells
Cancer Res., September 1, 2001; 61(17): 6555 - 6562.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. R. Shikhman, K. Kuhn, N. Alaaeddine, and M. Lotz
N-Acetylglucosamine Prevents IL-1{{beta}}-Mediated Activation of Human Chondrocytes
J. Immunol., April 15, 2001; 166(8): 5155 - 5160.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. van Triest, H. M. Pinedo, Y. van Hensbergen, K. Smid, F. Telleman, P. S. Schoenmakers, C. L. van der Wilt, J. A. M. van Laar, P. Noordhuis, G. Jansen, et al.
Thymidylate Synthase Level as the Main Predictive Parameter for Sensitivity to 5-Fluorouracil, but not for Folate-based Thymidylate Synthase Inhibitors, in 13 Nonselected Colon Cancer Cell Lines
Clin. Cancer Res., March 1, 1999; 5(3): 643 - 654.
[Abstract] [Full Text] [PDF]


Home page
Journal of Bioactive and Compatible PolymersHome page
L. A. Mccormick-Thomson, D. Sgouras, and R. Duncan
Poly(amino acid) Copolymers as a Potential Soluble Drug Delivery System. 2. Body Distribution and Preliminary Biocompatibility Testing In Vitro and In Vivo
Journal of Bioactive and Compatible Polymers, January 1, 1989; 4(3): 252 - 268.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1987 by the American Association for Cancer Research.